SKU LUM-BPC157-5 · C₆₂H₉₈N₁₆O₂₂ · 1419.55 g/mol · CAS 137525-51-0
A 15-amino-acid partial sequence of human gastric juice Body Protection Compound (GEPPPGKPADDAGLV). Lyophilized from acetate buffer; reconstitute with bacteriostatic water for in-vitro tissue-repair, angiogenesis, and tendon-fibroblast research.
Purity (HPLC)
≥ 99.18%
Endotoxin
< 0.5 EU/mg
Format
Lyophilized vial
Storage
−20 °C, desiccated
Shelf life
24 months from MFG
$90CAD/ 10 mg vial
In stock · Lot 26-A031
Qty
Add $300 for Free shipping
HPLC + MS verified per lot
~4 days typical to your door
COA bundled with shipment
Lot retains kept 5 years
Overview
BPC-157 (Body Protection Compound 157) is a stable 15-residue partial sequence derived from a protein found in human gastric juice. As a research reference standard it is used to investigate angiogenesis, fibroblast migration, and tendon-to-bone healing kinetics in cell-culture and rodent models. The pentadecapeptide retains activity in the gastric environment and shows characteristic stability under acid conditions that distinguishes it from many other peptide standards.
Each vial is lyophilized from acetate-buffered solution, sealed under nitrogen, and held through ship. Insulated tracked shipping is maintained from our lab to your bench.
Research applications
Tendon-fibroblast outgrowth and migration assays, in-vitro angiogenesis (HUVEC tube-formation), gastrointestinal mucosal-repair models, NO-pathway interaction studies, and growth-factor expression screens. Frequently paired with TB-500 in comparative musculoskeletal-repair protocols.
Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.
Identity
Parameter
Value
Sequence
GEPPPGKPADDAGLV
Molecular formula
C₆₂H₉₈N₁₆O₂₂
Molecular weight
1419.55 g/mol
CAS number
137525-51-0
Sequence length
15 residues
Quality
Test
Specification
HPLC purity
99.789%
Mass confirmation
ESI-MS within 0.5 Da
Net peptide content
≥ 80% by AAA
Endotoxin
< 0.5 EU/mg (LAL)
Bioburden
< 10 CFU/g
Residual TFA
< 1.0%
Lot 26-A031
Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Janoshik-tested with independent third-party HPLC verification. Retain samples held under storage spec for five years from release date.
Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.
Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.
Storage after reconstitution
Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.
Selected references
Sikiric P et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–32.
Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–80.
Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333.
Shipped in ~4 days typical via Xpresspost from Canada
Background research
What the literature says about Bpc 157.
Mechanism
Bpc 157 is Body Protection Compound 157, classified within the tissue-repair pathway. Structurally it is a stable gastric pentadecapeptide BPC 157. Sikiric et al. (2011) characterized BPC-157 as a stable gastric pentadecapeptide derived from human gastric juice. Subsequent in-vitro work has examined its action on tendon-fibroblast outgrowth, gastrointestinal-tract protection, and angiogenesis pathways via VEGFR2/eNOS signaling.
In an in-vitro setting, Bpc 157 interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable until reconstituted.
Common research applications
In-vitro receptor-binding and dose-response screens against the tissue-repair target panel.
Comparative pharmacology against related class members and previously published reference standards.
Time-course studies leveraging Bpc 157's known stability profile.
Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Bpc 157 arrives lyophilized in Canada Post (~4 days typical). On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
References
Sikiric P et al. Curr Pharm Des. 2011;17(16):1612-32.
Chang CH et al. J Appl Physiol. 2011;110(3):774-80.
Hsieh M-J et al. Mol Med Rep. 2017;15(4):1631-7.
For laboratory research only. Bpc 157 is sold strictly as an in-vitro reference standard. Sold as an in-vitro reference standard, not as a Health Canada or FDA-approved therapeutic.